A multicenter study showsPTENdeletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer

The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation

(2014) Mahul B. Amin et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer

(2014) Prabhakar Mithal et al.   INTERNATIONAL JOURNAL OF UROLOGY

Downgrading of biopsy based Gleason score in prostatectomy specimens

(2014) Kilian M Treurniet et al.   JOURNAL OF CLINICAL PATHOLOGY

Prognostic Histopathological and Molecular Markers on Prostate Cancer Needle-Biopsies: A Review

(2014) A. Marije Hoogland et al.   Biomed Research International

Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy

(2013) Sanoj Punnen et al.   EUROPEAN UROLOGY

Overdiagnosis and Overtreatment in Cancer

(2013) Laura J. Esserman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

A Model for the Design and Construction of a Resource for the Validation of Prognostic Prostate Cancer Biomarkers

(2012) Sarah Hawley et al.   ADVANCES IN ANATOMIC PATHOLOGY

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

(2012) Antje Krohn et al.   AMERICAN JOURNAL OF PATHOLOGY

Implications of the International Society of Urological Pathology Modified Gleason Grading System

(2012) Lars Egevad et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Systematic, evidence-based discovery of biomarkers at the NCI

(2012) John R. Prensner et al.   CLINICAL & EXPERIMENTAL METASTASIS

Active surveillance for low-risk prostate cancer

(2012) Chris H. Bangma et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Will Biomarkers Save Prostate Cancer Screening?

(2012) Matthew R. Cooperberg   EUROPEAN UROLOGY

Active Surveillance for Prostate Cancer: A Systematic Review of the Literature

(2012) Marc A. Dall’Era et al.   EUROPEAN UROLOGY

Upgrading and Downgrading of Prostate Cancer from Biopsy to Radical Prostatectomy: Incidence and Predictive Factors Using the Modified Gleason Grading System and Factoring in Tertiary Grades

(2012) Jonathan I. Epstein et al.   EUROPEAN UROLOGY

PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade

(2012) Maisa Yoshimoto et al.   MODERN PATHOLOGY

Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer

(2012) Alcides Chaux et al.   MODERN PATHOLOGY

Prostate-Cancer Mortality at 11 Years of Follow-up

(2012) Fritz H. Schröder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Versus Pathologic Staging for Prostate Adenocarcinoma

(2011) Ellen W. Cooke et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications

(2011) Maisa Yoshimoto et al.   GENES CHROMOSOMES & CANCER

Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance

(2011) Sima P. Porten et al.   JOURNAL OF CLINICAL ONCOLOGY

Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy

(2011) Scott E. Eggener et al.   JOURNAL OF UROLOGY

PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer

(2010) Tarek A. Bismar et al.   BJU INTERNATIONAL

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

(2010) A H M Reid et al.   BRITISH JOURNAL OF CANCER

TMPRSS2–ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features

(2010) Samson W Fine et al.   MODERN PATHOLOGY

Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer

(2009) K. G. Hermans et al.   CLINICAL CANCER RESEARCH

PTENgenomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer

(2009) Kanishka Sircar et al.   JOURNAL OF PATHOLOGY

Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context

(2009) G. Draisma et al.   JNCI-Journal of the National Cancer Institute

Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005

(2009) H. G. Welch et al.   JNCI-Journal of the National Cancer Institute

Cancer Screening: The Clash of Science and Intuition

(2008) Barnett S. Kramer et al.   Annual Review of Medicine